VK-1727

• Description :

  VK-1727 is a selective small molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 selectively blocks the proliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple sclerosis research[1].

• UNSPSC :

  12352005

• Target :

  EBV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/vk-1727.html

• Purity :

  99.88

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(OC)C1=CC=CC(C#CC2=CC=C(OC3CCOCC3)C=C2)=C1C4=CC5=C(C=C4)C=CN5

• Molecular Formula :

  C29H25NO4

• Molecular Weight :

  451.51

• References & Citations :

  [1]Monaco MCG, et al. EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls. Neurol Neuroimmunol Neuroinflamm. 2023 Aug 10;10 (5) :e200149.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported